PIPA: Combination of PI3 Kinase Inhibitors and PAlbociclib
Status: UNKNOWN
Study type: INTERVENTIONAL
Conditions: Advanced Solid Tumours|Breast Cancer
Interventions: DRUG: Palbociclib + Taselisib / Pictilisib
Sponsor: Royal Marsden NHS Foundation Trust
Collaborators: Institute of Cancer Research, United Kingdom|Roche Pharma AG|Pfizer